Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiography, Thoracic | 16 | 2021 | 331 | 2.480 |
Why?
|
| Lung Neoplasms | 32 | 2019 | 2457 | 2.240 |
Why?
|
| Solitary Pulmonary Nodule | 18 | 2016 | 141 | 1.820 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 18 | 2024 | 462 | 1.610 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2024 | 2666 | 1.500 |
Why?
|
| Diagnosis, Computer-Assisted | 10 | 2015 | 337 | 1.230 |
Why?
|
| Radiographic Image Enhancement | 11 | 2015 | 449 | 1.170 |
Why?
|
| Pleural Neoplasms | 3 | 2024 | 207 | 0.790 |
Why?
|
| Mesothelioma | 3 | 2024 | 346 | 0.730 |
Why?
|
| Lung | 9 | 2023 | 1406 | 0.690 |
Why?
|
| Tomography, Spiral Computed | 6 | 2018 | 75 | 0.580 |
Why?
|
| Observer Variation | 16 | 2016 | 579 | 0.580 |
Why?
|
| Pattern Recognition, Automated | 7 | 2009 | 218 | 0.520 |
Why?
|
| Radiology | 4 | 2016 | 215 | 0.510 |
Why?
|
| ROC Curve | 15 | 2016 | 793 | 0.490 |
Why?
|
| Radiologists | 3 | 2021 | 59 | 0.450 |
Why?
|
| Thorax | 1 | 2015 | 77 | 0.430 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 2 | 2011 | 18 | 0.420 |
Why?
|
| Sensitivity and Specificity | 17 | 2015 | 1944 | 0.410 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 467 | 0.400 |
Why?
|
| Aged | 26 | 2024 | 21701 | 0.400 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2080 | 0.390 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 7386 | 0.370 |
Why?
|
| Mass Screening | 5 | 2005 | 745 | 0.350 |
Why?
|
| Middle Aged | 25 | 2024 | 29352 | 0.350 |
Why?
|
| Algorithms | 7 | 2009 | 2001 | 0.340 |
Why?
|
| Bone and Bones | 1 | 2012 | 270 | 0.330 |
Why?
|
| Pneumonia | 1 | 2012 | 195 | 0.320 |
Why?
|
| False Positive Reactions | 11 | 2009 | 215 | 0.310 |
Why?
|
| Reproducibility of Results | 11 | 2021 | 2783 | 0.300 |
Why?
|
| Diagnostic Errors | 6 | 2009 | 161 | 0.290 |
Why?
|
| Humans | 48 | 2024 | 97893 | 0.270 |
Why?
|
| Female | 30 | 2024 | 51463 | 0.270 |
Why?
|
| Male | 29 | 2024 | 46995 | 0.260 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2009 | 322 | 0.260 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1567 | 0.250 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 630 | 0.210 |
Why?
|
| Retrospective Studies | 9 | 2019 | 10947 | 0.200 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 3272 | 0.200 |
Why?
|
| Bite Force | 1 | 2023 | 34 | 0.200 |
Why?
|
| Subtraction Technique | 5 | 2011 | 126 | 0.190 |
Why?
|
| Emphysema | 1 | 2023 | 24 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2373 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 44 | 0.180 |
Why?
|
| Clinical Competence | 6 | 2019 | 863 | 0.180 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 61 | 0.180 |
Why?
|
| Radiation Dosage | 6 | 2005 | 231 | 0.170 |
Why?
|
| Tumor Burden | 2 | 2024 | 330 | 0.160 |
Why?
|
| Lung Diseases | 5 | 2007 | 284 | 0.150 |
Why?
|
| Fossils | 1 | 2023 | 414 | 0.150 |
Why?
|
| Smoking | 1 | 2003 | 674 | 0.150 |
Why?
|
| Machine Learning | 1 | 2021 | 406 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 12 | 0.130 |
Why?
|
| Illinois | 1 | 2019 | 522 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2017 | 32 | 0.120 |
Why?
|
| Indans | 1 | 2017 | 40 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2017 | 90 | 0.120 |
Why?
|
| Spinal Fractures | 2 | 2008 | 104 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 100 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 107 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 171 | 0.110 |
Why?
|
| Adult | 9 | 2015 | 29453 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 422 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2017 | 351 | 0.100 |
Why?
|
| Survival Rate | 1 | 2019 | 2040 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 642 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2015 | 1094 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2019 | 2580 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2004 | 1211 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 588 | 0.090 |
Why?
|
| Software | 3 | 2012 | 693 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 642 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 94 | 0.080 |
Why?
|
| Image Enhancement | 2 | 2011 | 503 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2008 | 1302 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 239 | 0.080 |
Why?
|
| Probability | 2 | 2024 | 356 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 407 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2011 | 249 | 0.070 |
Why?
|
| Artificial Intelligence | 3 | 2009 | 473 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2009 | 100 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 359 | 0.070 |
Why?
|
| Thoracic Diseases | 1 | 2008 | 28 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1173 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2012 | 470 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2008 | 159 | 0.060 |
Why?
|
| Fractures, Compression | 1 | 2006 | 22 | 0.060 |
Why?
|
| Liver | 1 | 2011 | 1231 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1778 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2017 | 305 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2003 | 399 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2006 | 135 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2004 | 148 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 354 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 116 | 0.050 |
Why?
|
| S-Adenosylmethionine | 1 | 2023 | 28 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2003 | 64 | 0.050 |
Why?
|
| Calcinosis | 1 | 2004 | 220 | 0.050 |
Why?
|
| Japan | 1 | 2003 | 303 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2017 | 1392 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1995 | 0.050 |
Why?
|
| Registries | 1 | 2008 | 1120 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2023 | 218 | 0.040 |
Why?
|
| Young Adult | 1 | 2015 | 7504 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 146 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2023 | 515 | 0.040 |
Why?
|
| Adolescent | 1 | 2015 | 10078 | 0.040 |
Why?
|
| Skull | 1 | 2023 | 278 | 0.040 |
Why?
|
| Biopsy | 1 | 2004 | 1224 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 2892 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2016 | 258 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 521 | 0.040 |
Why?
|
| Prevalence | 1 | 2003 | 1384 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3606 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1776 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 660 | 0.030 |
Why?
|
| Cytochrome c Group | 1 | 1998 | 82 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1105 | 0.030 |
Why?
|
| Rats | 1 | 2023 | 4071 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 4023 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 86 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 212 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1998 | 185 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 356 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 425 | 0.030 |
Why?
|
| Automation | 2 | 2006 | 118 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 294 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 214 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 968 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 530 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 1028 | 0.030 |
Why?
|
| DNA Repair | 1 | 2017 | 363 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 902 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 1014 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2018 | 745 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 920 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 550 | 0.020 |
Why?
|
| Quality Control | 2 | 2003 | 130 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 1555 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1946 | 0.020 |
Why?
|
| Risk Factors | 1 | 2002 | 6224 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1998 | 900 | 0.020 |
Why?
|
| Apoptosis | 1 | 1998 | 1752 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1790 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1998 | 2023 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12707 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4112 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 1513 | 0.020 |
Why?
|
| Computers | 1 | 2006 | 102 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 96 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 9682 | 0.010 |
Why?
|
| Mammography | 1 | 2008 | 504 | 0.010 |
Why?
|
| Mobile Health Units | 1 | 2003 | 12 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 28910 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 62 | 0.010 |
Why?
|
| Expert Systems | 1 | 2003 | 18 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2003 | 64 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 600 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 1145 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5555 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 57 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 2008 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 1619 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 2483 | 0.010 |
Why?
|